hydroxychloroquine has been researched along with Ataxia in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since the emergence of coronavirus disease 2019 (COVID-19), neurological symptoms, syndromes, and complications associated with this multi-organ viral infection have been reported and the various aspects of neurological involvement are increasingly uncovered." | 2.72 | Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. ( Aghavali, S; Babadi, M; Daraie, P; Emamikhah, M; Jalili, M; Mehrabani, M; Mohaghegh, F; Pouranian, M; Rohani, M; Zaribafian, M, 2021) |
| "Hydroxychloroquine is an oral antimalarial medication commonly used off-label for a variety of rheumatological conditions, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and dermatomyositis." | 1.46 | Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. ( Chansky, PB; Werth, VP, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akula, SM | 1 |
| McCubrey, JA | 1 |
| Emamikhah, M | 1 |
| Babadi, M | 1 |
| Mehrabani, M | 1 |
| Jalili, M | 1 |
| Pouranian, M | 1 |
| Daraie, P | 1 |
| Mohaghegh, F | 1 |
| Aghavali, S | 1 |
| Zaribafian, M | 1 |
| Rohani, M | 1 |
| Chansky, PB | 1 |
| Werth, VP | 1 |
2 reviews available for hydroxychloroquine and Ataxia
| Article | Year |
|---|---|
Where are we with understanding of COVID-19?
Topics: Antiviral Agents; Ataxia; Betacoronavirus; Communicable Disease Control; Coronavirus Infections; COV | 2020 |
Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature.
Topics: Adult; Anticonvulsants; Ataxia; Azithromycin; Clonazepam; Cough; COVID-19; COVID-19 Drug Treatment; | 2021 |
1 other study available for hydroxychloroquine and Ataxia
| Article | Year |
|---|---|
Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy.
Topics: Ataxia; Drug Overdose; Female; Humans; Hydroxychloroquine; Middle Aged; Paresthesia; Tinnitus; Visio | 2017 |